Join our daily newsletter At The Bell to receive exclusive market insights
- Volpara Health Technologies (VHT) has been granted another patent from the European patent office covering the company’s method of image quantification
- The patent covers the company’s improved breast cancer screening analysis and is effective across 25 European countries
- Research suggests patients could benefit from a baseline mammogram to assess their breast cancer risk before the standard screening age of 40
- Volpara Chief Financial Officer Craig Hadfield says the company’s patent portfolio forms part of its broader sales and growth strategy
- Volpara Health Technologies shares closed today’s session down 3.33 per cent to trade at $1.16
Volpara Health Technologies (VHT) has been granted another patent from the European patent office covering the company’s method of image quantification.
The latest patent, which is effective across 25 European countries, takes the company’s total patent portfolio to 98.
Specifically, Volpara said the patent covers its improved analysis of low-dose images, enabling a more accurate assessment of a woman’s breast composition at an early age and calculating her baseline risk of breast cancer.
Volpara Chief Financial Officer Craig Hadfield commented on the patent win.
“These patents work together with Volpara’s other international intellectual property rights to facilitate the sales and growth strategy for Volpara’s product line,” he said.
The company said research studies suggest patients should receive a baseline mammogram to assess their breast cancer risk before they reach the standard screening age of 40.
A patient considered high risk may then be directed to begin annual screenings earlier than usual.
Volpara is looking to provide high-sensitivity, low-dose cancer screening for women between the ages of 25 and 30 without the radiation effects typically associated with standard cancer screenings.
Volpara Health Technologies shares closed today’s session down 3.33 per cent to trade at $1.16.
